Mwyngil Therapeutics Announces Positive in vivo Proof of Concept Data for First-in-Class GPR75 Inverse Agonist in Obesity and Cardiometabolic Disease.
Lead oral compounds demonstrated up to 25% body weight reduction with preferential fat loss, preserved lean mass, and broad metabolic improvements in DIO models
Excerpt from the Press Release:
BOSTON, June 25, 2026 /PRNewswire/ — Mwyngil Therapeutics, a biotech company focused on developing innovative small molecule therapeutics for cardiometabolic disease, today announced positive in vivo proof-of-concept results from its GPR75 inverse agonist program, supporting the potential of GPR75 modulation as a differentiated therapeutic approach for obesity and cardiometabolic disease. In a 4-week, diet-induced obesity (DIO) mouse model, orally administered lead compounds produced dose-dependent body weight reduction of up to 25% versus vehicle while preserving lean mass across all tested doses. Importantly, weight reduction was accompanied by preferential loss of adipose tissue rather than muscle, with a 33–50% reduction in fat rate and up to 1.5-fold reduction in epididymal white adipose tissue (eWAT). Additional in vivo findings demonstrated broad metabolic improvements beyond body weight reduction, including:
- Ameliorated glycemic control with reductions in fasting blood glucose and HbA1c
- Reductions of systemic inflammatory markers, including CRP and IL-18
- Reduced liver weight and improvement of hepatic and lipid biomarkers including ALT/AST and LDL/total cholesterol
“These data suggest that GPR75 inverse agonism may offer a differentiated obesity profile focused on quality weight loss rather than weight reduction alone,” said Luba Greenwood, CEO of Mwyngil Therapeutics. “We observed robust body weight reduction together with preservation of lean mass and improvements across multiple metabolic parameters, supporting the broader role of GPR75 in systemic metabolic regulation.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?